FARN Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy (FRA:4FR) reports robust frontline data and a strengthened cash position, setting the stage for the BEXERA trial readout in late 2027.

Faron Pharmaceuticals Limited (AIM:FARN) is set to start its phase IIb BEXERA trial for blood cancer drug bexmarilimab in the second half of this year. It'll test the drug in 90 patients across the US, Europe and the UK, funded by a €40 million rights issue. Central Asia Metals PLC (AIM:CAML, OTC:CAMLF) has nearly doubled first-half earnings on higher copper and zinc prices plus higher output. Profit before tax jumped 203%, and the interim dividend's been lifted to 8p. Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) has completed drone testing with QinetiQ on its sulfur battery cathode material. Cells handled repeated high-power take-off and landing cycles with barely any performance loss. S&U PLC (LSE:SUS) has hit record capital receivables of £616 million for its first half, up 20% on last year. Growth's been led by its motor finance arm Advantage, where deal numbers jumped 50%. Mila Resources PLC (LSE:MILA) has roughly doubled the gold resource at its Coffey deposit in Western Australia. It's now sitting at 41,300 ounces, with the company saying the system could extend well beyond the current resource. Georgina Energy PLC (LSE:GEX) has completed a £1.25 million fundraise to advance its Mount Winter project. Investors also get a warrant for every share, exercisable at 14p over the next five years. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.